FDA Adds a GLP-1 Eye Warning
Labels for Ozempic, Wegovy, Mounjaro, Zepbound and every other drug in the class must now note a potential increased risk of a rare optic nerve condition.

Archive photo: The Food and Drug Administration's headquarters in Silver Spring, Maryland, March 2015.Illustration by The Good Times, based on a photo by the U.S. Food and Drug Administration (public domain)
The Food and Drug Administration is requiring makers of all GLP-1 medicines, the class that includes Ozempic, Wegovy, Mounjaro and Zepbound, to add a warning about a potential increased risk of a rare eye condition that can cause sudden, permanent vision loss. The condition, nonarteritic anterior ischemic optic neuropathy, or NAION, cuts blood flow to the front of the optic nerve and usually affects one eye. In the FDA's analysis of 126 clinical trials, there were 6.4 cases per 100,000 patient-years among people taking GLP-1 drugs and 3.8 among those on comparison treatments, out of 15 probable cases in all. An FDA study of real-world health records found no significant increase compared with one other class of diabetes drugs, but a higher risk compared with another. The agency found no biological mechanism in animal data. It advises patients with sudden vision changes to seek care right away and to discuss with a clinician whether to keep taking the drug.
The Food and Drug Administration is requiring the makers of every GLP-1 receptor agonist to add information about a potential increased risk of a rare but serious eye condition to the Warnings and Precautions section of their labels.
The drugs, which mimic a gut hormone that lowers blood sugar after meals and curbs appetite, are widely used for Type 2 diabetes and for weight loss. The requirement covers the whole class, including Novo Nordisk's Ozempic and Wegovy, Eli Lilly's Mounjaro and Zepbound, older diabetes medicines such as Victoza and Trulicity, and Foundayo, approved this year. Spokespeople for Novo Nordisk and Lilly said patient safety was their top priority.
The condition
Nonarteritic anterior ischemic optic neuropathy, or NAION, occurs when blood flow to the front of the optic nerve is reduced. It typically causes sudden, painless loss of vision in one eye, sometimes noticed on waking, and the loss can be permanent; there is no known treatment. Its underlying cause is not fully understood, and its risk factors, including diabetes, high blood pressure and sleep apnea, overlap with conditions common among people who take GLP-1 drugs. In adults over 50, the general rate is about 2.3 to 10.2 cases per 100,000 people a year, the FDA said.
What the agency found
The FDA began its review after a 2024 study in JAMA Ophthalmology reported a higher rate of NAION among diabetes patients prescribed semaglutide. The agency said it found several limitations in that study but judged that further assessment was warranted.
The agency then pooled 126 randomized trials involving more than 134,000 patients. It identified 15 probable NAION cases, 10 among GLP-1 users and five among those on placebo, a rate of 6.4 per 100,000 patient-years compared with 3.8. A separate FDA study of real-world health data on adults with Type 2 diabetes found no statistically significant increase compared with SGLT-2 inhibitors, another diabetes drug class, but an increased risk compared with DPP-4 inhibitors. The agency said more rigorous published observational studies consistently pointed to an increased risk, and NAION cases have been reported for every GLP-1 drug on the market. Its review of animal data found no mechanism by which the drugs could raise the risk.
The FDA advises patients and caregivers to contact a health professional right away about sudden vision loss, blurred or missing areas of vision, or changes in color. Patients who have had NAION should discuss whether to continue the medication, and the agency tells clinicians to consider stopping it in those patients unless the benefits clearly outweigh the risk.